HKU Study Promises New Treatment For Influenza
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "http://newsstatic.rthk.hk/audios/mfile_1401896_1_20180615154932.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.htm', 'DCS.dcsqry', '' ); } } }); }); });
2018-06-15 HKT 17:53
Hong Kong University researchers say they've achieved a world first in the fight against influenza, by curing infected mice using a doctored version of the flu virus.
Lead researcher Yuen Kwok-yung said this new kind of treatment promises to be more effective than existing drugs like Tamiflu or Relenza, which are only effective when administered within days of the patient falling ill, and for which viruses can quickly develop resistance.
The new treatment effectively turns the flu virus against itself. Researchers cuts away certain key genes from the virus, which prevents it from replicating normally. This 'defective interfering gene' treatment, dubbed DIG3, is therefore resistant to mutation because the virus recognises it as one of its own.
"The cell is being cheated... it's treated as the normal influenza virus. And so we do not expect mutations to develop against the defective interfering genes", Yuen said.
Another researcher, Kelvin To, said their study is the "first time in the world that defective interfering gene has been successfully demonstrated to cure mice from influenza."
"In this study, we have tested H7N7 and H1N1, but we believe that it should theoretically be able to fight against other subtypes of influenza viruses as well," he added.
However, researchers caution that it can take decades of development, clinical trials and adjustments, costing billions of dollars, before the technology can lead to new drugs actually being introduced to the market.
"We have a patent, and we're waiting for investors and companies to develop [the treatment] further in clinical trials et cetera. And we hope that, with the government's emphasis on innovation and technology, there would be money coming in to develop this into a marketable drug one day", Yuen said.
OCBC Plans Hong Kong Wealth Expansion With Up To 50 New Bankers
OCBC is expending its wealth management team in Hong Kong by 30% this year to meet growing regional demand for investme... Read more
Hana Financial To Acquire US$669M Stake In Dunamu, Deepening Crypto Push
Hana Financial Group has agreed to acquire a 6.55% stake in digital asset operator Dunamu. The transaction is valued at... Read more
Reap And TerraPay Partner To Expand Cross-Border Payouts Via Local Payment Rails
Reap has partnered with TerraPay to expand its cross-border payout network using domestic clearing systems. The integra... Read more
Tencent Fintech And Cloud Services Lift Q1 2026 Revenue 9% To US$8.68 Billion
Tencent reported a 9% increase in revenue from its fintech and business services division for the first quarter of 2026... Read more
Ant Group Profit Falls An Estimated 79% As AI And Payments Spending Rises
Ant Group saw an estimated 79% decline in quarterly profit as the company accelerates its spending on AI, large languag... Read more
Alibabas Cloud Revenue Jumps 40% As AI Investments Pressure Profitability
Alibaba Group has released its financial results for the quarter and fiscal year ending 31 March 2026, reporting a 3% a... Read more


